One Step Rapid Syphilis Test Kit by QL BioTech – Fast & Reliable

Short Description:

The Filariasis IgG/IgM Rapid Test Device (Whole Blood/Serum/Plasma) is a lateral flow immunoassay for the simultaneous detection and differentiation of IgG and IgM anti-lymphatic filarial parasites (W. Bancrofti and B. Malayi) in human serum, plasma or whole blood. This test is intended to be used as a screening test and as an aid in the diagnosis of infection with lymphatic filarial parasites. Any reactive specimen with the Filariasis IgG/IgM Rapid Test must be confirmed with alternative testing method(s).


Product Detail

Product Tags

Introducing QL BioTech's latest innovation in the realm of medical diagnostics – the One Step Rapid Syphilis Test Device. Designed for precision, quick turnaround, and ease of use, this rapid test device marks a milestone in the efficient detection and management of syphilis. With the global rise in sexually transmitted infections (STIs), having access to reliable, quick, and easy-to-administer testing solutions is more crucial than ever. QL BioTech stands at the forefront of this battle, offering a robust solution that caters to the needs of healthcare professionals and patients alike.

Product Detail

Brand: QL

Specimens: : Whole Blood/Serum/Plasma

Reading time: in 15 minutes.

Pack:25 T

STORAGE  2‐30°C

KIT COMPONENTS(Device)

Individually packed test devices

Each device contains a strip with colored conjugates

and reactive reagents pre-spreaded at the

corresponding regions

Disposable pipettes

For adding specimens use

Buffer

Phosphate buffered saline and preservative

Package insert

For operation instruction

SUMMARY AND EXPLANATION OF THE TEST

The lymphatic filariasis known as Elephantiasis, mainly caused by W. bancrofti and B. malayi, affects about 120 million people over 80 countries1,2. The disease is transmitted to humans by

the bites of infected mosquitoes within which the microflariae sucked from an infected human subject develops into third-stage larvae. Generally, repeated and prolonged exposure to infected larvae is required for establishment of human infection.

The definitive parasitologic diagnosis is the demonstration of microflariae in blood samples3.

However, this gold standard test is restricted by the requirement for nocturnal blood collection and lack of adequate sensitivity. Detection of circulating antigens is commercially available. Its

usefulness is limited for W. bancrofti4. In addition, microfilaremia and antigenemia develop from months to years after exposure.

Antibody detection provides an early means to detect filarial parasite infection. Presence of IgM to the parasite antigens suggest current infection, whereas, IgG corresponds to late stage of infection or past infection5. Furthermore, identification of conserved antigens allows ‘pan-filaria’ test to be applicable. Utilization of recombinant proteins eliminates cross-reaction with

individuals having other parasitic diseases6. The Filariasis IgG/IgM Rapid Test uses conserved recombinant antigens to simultaneously detect IgG and IgM to the W. bancrofti and B. malayi parasites without the restriction on specimen collection.

ASSAY PROCEDURE

Bring the specimen and test components to room temperature if refrigerated or frozen. Place the test device on a clean, flat surface.
For whole blood test

Apply 1 drop of whole blood (about 40-50 µL) into the sample well. Then add 1 drop (about 35-50 µL) of Sample Diluent immediately.

For serum or plasma test

Fill the pipette dropper with the specimen. Holding the dropper vertically, dispense 1 drop (about 30-45 µL) of specimen into the sample well making sure that there are no air bubbles.

Then add 1 drop (about 35-50 µL) of Sample Diluent immediately.

Set up timer. Results can be read in 15 minutes. Positive results can be visible in as short as 1 minute. Don’t read result after 15 minutes.

INTERPRETATION OF ASSAY RESULT


1.In addition to the presence of C band, if only T1 band is  developed, the test indicates for the presence of anti-W. bancrofti  or B. malayi IgG antibody. The result is positive.
2.In addition to the presence of C band, if only T2 band is  developed, the test indicates for the presence of anti-W. bancrofti  or B. malayi IgM antibody. The result is positive.
3.In addition to the presence of C band, both T1 and T2 bands are  developed, the test indicates for the presence of both IgG and IgM  anti-W. bancrofti or B. malayi. The result is also positive.



If only the C band is present, the absence of any burgundy color in the both test bands (T1 and T2) indicates that no anti-W. bancrofti or -B. malayi antibody is detected in the specimen. The

result is negative.

If no C band is developed, the assay is invalid regardless of any burgundy color in the test bands. Repeat the assay with a new device.



Crafted with precision and the user's ease in mind, the One Step Rapid Syphilis Test Device utilizes a state-of-the-art immunochromatographic assay to detect both IgG and IgM antibodies to Treponema Pallidum (TP) in human whole blood, serum, or plasma with remarkable accuracy. This dual-detection model increases the test’s sensitivity and reliability, making it a pivotal tool in the early diagnosis and treatment of syphilis. The intuitive design allows for the test to be conducted in a wide range of settings, from sophisticated labs to the more basic setups of remote clinics, without the need for extensive training or specialized equipment. The process is straightforward and yields results within just 15 minutes. This rapid turnaround not only enhances patient care through timely diagnosis but also significantly cuts down the waiting period that can often add to patient anxiety. The One Step Rapid Syphilis Test Device by QL BioTech is a testament to the company's commitment to advancing healthcare diagnostics. It underscores the importance of accessibility to reliable testing options, especially in an era where the prevalence of STIs calls for urgent and immediate action. By providing an efficient, accurate, and user-friendly testing solution, QL BioTech empowers healthcare providers worldwide to offer better care and contribute to the global effort of STI control and prevention.

  • Previous:
  • Next: